The global Guillain barre syndrome treatment market is anticipated to grow at a significant CAGR of 5.2% during the forecast period 2022-2028. As per the information provided by the United Nations, in 2020, there are an estimated 727 million persons aged 65 years or over across. Additionally, this number is projected to be more than double by 2050, reaching over 1.5 billion persons. So, the increasing elderly population, which leads to the pervasiveness of immunological illnesses is one of the primary factors driving the expansion of the guillain barre syndrome market.
Get Free Sample link @ https://www.omrglobal.com/request-sample/guillain-barre-syndrome-treatment-market
Further, the key players operating in the global guillain barre syndrome treatment market had been adopting strategies such as new launches and agreements to gain major market share. For instance, in November 2021, Biotest AG announced the authorization in France for the human intravenous immunoglobulin preparation that is Intratect which is manufactured and marketed by Biotest in two concentrations. The Intratect is an important component of Biotest’s portfolio with over 50 approvals globally. The broad spectrum of indications includes substitution therapy for primary and secondary immunodeficiency diseases along with immunomodulation for primary immune thrombocytopenia, Guillain-Barré syndrome, and Kawasaki syndrome, among others. Further, in September 2019, Annexon Biosciences Inc., announced that the FDA had granted fast track designation to ANX005, a novel treatment for Guillain-Barré syndrome. ANX005 is a clinical-stage investigational monoclonal antibody intended to treat patients with autoimmune and neurodegenerative disorders and formulated for IV administration.
A full report of Global Guillain Barre Syndrome Treatment Market available @ https://www.omrglobal.com/industry-reports/guillain-barre-syndrome-treatment-market
- Market Coverage
- Market number available for – 2022-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered- By Source, By Product Type, By Applications
- Competitive Landscape- Archer Daniels Midland Co., Ingredion Inc., Kerry Group Plc, Cargill Inc., and others
Global Guillain Barre Syndrome Treatment Market Report Segment
By Type
- Intravenous Immunoglobulin
- Plasma Exchange
- Others (Anticonvulsants and LMWH)
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Others
Global Guillain Barre Syndrome Treatment Market Report Segment by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Italy
- Spain
- France
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- Rest of Asia-Pacific
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global Guillain barre syndrome treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/guillain-barre-syndrome-treatment-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404
